Ptd-smad7 therapeutics
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsXiao-Jing WANG, Qinghong ZHANG, Yosef REFAELI
Life of this patent
Estimating the term…
Abstract
The present technology provides methods and compositions for the treatment of inflammatory and/or tissue damage conditions. In particular, the use of Smad7 compositions delivered locally or systemically to a site of inflammation and/or tissue damage is described. Other specific embodiments concern treatment or prevention of side effects caused by radiation and/or chemotherapy, including but not limited to oral and gastric mucositis. Also provided are codon-optimized nucleic acids encoding for Smad7 fusion proteins.
Claims17
-20. (canceled)
A fusion protein comprising a protein transduction domain and a functional Smad7 domain, wherein the functional domain is selected from the group consisting of amino acids 2-258 of the amino acid sequence as set forth in SEQ ID NO:
- 12 and amino acids 259-426 of the amino acid sequence as set forth in SEQ ID NO:
- 12.
A nucleic acid molecule encoding a fusion protein comprising a protein transduction domain and a functional Smad7 domain, wherein the functional domain is selected from the group consisting of amino acids 2-258 of the amino acid sequence as set forth in SEQ ID NO:
- 12 and amino acids 259-426 of the amino acid sequence as set forth in SEQ ID NO:
- 12.
A method for preventing or treating an inflammatory disease or disorder in a subject, comprising providing to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a fusion protein comprising a protein transduction domain and a functional Smad7 domain, wherein the functional domain is selected from the group consisting of amino acids 2-258 of the amino acid sequence as set forth in SEQ ID NO:
- 12 and amino acids 259-426 of the amino acid sequence as set forth in SEQ ID NO:
- 12.
Dependencies are inferred from the claim text.